Krystal Biotech (NASDAQ:KRYS) Hits New 12-Month High Following Better-Than-Expected Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) shares hit a new 52-week high on Wednesday following a better than expected earnings announcement. The stock traded as high as $298.30 and last traded at $287.84, with a volume of 842516 shares changing hands. The stock had previously closed at $276.45.

The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. The company had revenue of $107.11 million for the quarter, compared to analysts’ expectations of $105.30 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%.

Krystal Biotech News Summary

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q4 revenue and EPS beat — VYJUVEK net product revenue of $107.1M (Q4) and $389.1M (FY), and EPS that topped estimates, supporting higher near‑term profitability. Krystal Biotech Announces Q4 and FY2025 Results
• Positive Sentiment: Regulatory designations accelerate development: FDA granted RMAT to KB707 (advanced NSCLC) and Fast Track to KB111 (Hailey‑Hailey disease), which can speed review and regulatory interactions. Quiver: 4Q Revenue & FDA Designations
• Positive Sentiment: Strong balance sheet — ~$956M in cash and investments at year‑end provides runway for multiple trials and commercialization efforts. Quiver: Cash Position
• Neutral Sentiment: Positive clinical signals in respiratory programs (KB407 cystic fibrosis cohort showed lung delivery/expression; CORAL‑3 repeat‑dose study discussions with FDA planned), supporting longer‑term upside but still early stage. GlobeNewswire: Pipeline Updates
• Negative Sentiment: The company raised FY‑2026 non‑GAAP combined R&D & SG&A guidance but did not provide a GAAP reconciliation because it cannot confidently estimate stock‑based comp — this increases uncertainty about true GAAP expense and margins. GlobeNewswire: Guidance Note
• Negative Sentiment: Rising operating costs — SG&A increased year‑over‑year (notably stock‑based comp), which could pressure operating leverage as commercialization expands. GlobeNewswire: Expense Details
• Negative Sentiment: European rollout timing risk — pricing negotiations in Germany and France could delay broader European revenue; reimbursement timelines extend into 2026–2027. Quiver: Europe Pricing Risk
• Neutral Sentiment: Investor materials and earnings call transcript provide more color on commercial cadence and trial timelines — useful for due diligence. Seeking Alpha: Earnings Call Transcript

Analysts Set New Price Targets

A number of brokerages recently commented on KRYS. Citigroup increased their price target on shares of Krystal Biotech from $320.00 to $336.00 and gave the company a “buy” rating in a report on Monday, January 12th. Zacks Research lowered Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a report on Monday, December 29th. Jefferies Financial Group increased their price target on Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Bank of America lifted their price objective on shares of Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Nine research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $291.89.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the sale, the insider directly owned 1,413,711 shares of the company’s stock, valued at approximately $311,242,613.76. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Kathryn Romano sold 12,500 shares of the company’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the completion of the transaction, the chief accounting officer owned 19,318 shares in the company, valued at approximately $5,257,200.52. The trade was a 39.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 13.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of hedge funds have recently added to or reduced their stakes in KRYS. Avoro Capital Advisors LLC increased its position in shares of Krystal Biotech by 4.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,888,888 shares of the company’s stock worth $712,226,000 after acquiring an additional 111,111 shares during the period. State Street Corp grew its stake in Krystal Biotech by 10.5% in the second quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after purchasing an additional 128,639 shares in the last quarter. Soleus Capital Management L.P. increased its holdings in Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after purchasing an additional 481,200 shares during the period. Braidwell LP increased its holdings in Krystal Biotech by 81.6% during the 2nd quarter. Braidwell LP now owns 727,811 shares of the company’s stock worth $100,045,000 after purchasing an additional 327,067 shares during the period. Finally, Geode Capital Management LLC raised its position in Krystal Biotech by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock valued at $85,174,000 after purchasing an additional 7,194 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Stock Performance

The company has a fifty day simple moving average of $263.97 and a two-hundred day simple moving average of $207.87. The firm has a market capitalization of $8.35 billion, a PE ratio of 43.15 and a beta of 0.49.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.